Our study showed that sitagliptin use was associated with an increasedrisk of HHF in patients with T2DM receiving dialysis, especially in those withoutsevere hypoglycemia, without ACE inhibitors treatment, with prior HF or receivinghemodialysis. Here, ACE is linked to Hypoglycemia.